CSF3 and leiomyosarcoma: Doxorubicin as single agent or in combination with ifosfomide and/or dacarbazine was considered standard, first-line chemotherapy [1,2], until Hensley and colleagues reported outcomes with fixed-dose gemcitabine (G) 900 mg/m2 administered at days 1 and 8, docetaxel (D) 100 mg/m2 at day 8, with granulocyte colony-stimulating factor (GCSF) support in 34 patients with advanced leiomyosarcoma (LMS) and showed a 53% overall response rate (RR) [3].